Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | Carboplatin + LY4170156 |
| Synonyms | |
| Therapy Description | |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| Carboplatin | Paraplatin | CBDCA | Chemotherapy - Platinum 7 | Paraplatin (carboplatin) is a second-generation platinum compound and is activated intracellularly to form reactive platinum complexes that cross link DNA with DNA and with proteins. This induces apoptosis and inhibits cell growth (NCI Drug Dictionary). |
| LY4170156 | LY-4170156|LY 4170156 | FOLR1-targeted Therapy 24 | LY4170156 is an antibody-drug conjugate (ADC) comprising a monoclonal antibody against FOLR1 (folate receptor alpha; FRa) linked to the topoisomerase I inhibitor exatecan, which may induce apoptosis and inhibit proliferation of tumor cells expressing FOLR1 (FRa) (J Clin Oncol (2024) 42:16_suppl, 3023, NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT06400472 | Phase I | Bevacizumab + LY4170156 LY4170156 + Pembrolizumab Carboplatin + LY4170156 LY4170156 Itraconazole + LY4170156 | A Study of LY4170156 in Participants With Selected Advanced Solid Tumors | Recruiting | USA | ITA | FRA | ESP | AUS | 2 |